S. I. Hallan, J. Coresh, B. C. Astor, A. Asberg, N. R. Powe et al., International comparison of the relationship of chronic kidney disease prevalence and ESRD risk, J. Am. Soc. Nephrol, vol.17, pp.2275-2284, 2006.

V. Jha, G. Garcia-garcia, K. Iseki, Z. Li, S. Naicker et al., Chronic kidney disease: global dimension and perspectives, Lancet, vol.382, pp.260-272, 2013.

A. Ojo, Addressing the global burden of chronic kidney disease through clinical and translational research, Trans. Am. Clin. Climatol. Assoc, vol.125, pp.229-243, 2014.

R. Steenkamp, C. Castledine, T. Feest, and D. Fogarty, UK RRT prevalence in 2009: national and centre-specific analyses, Registry 13th Annual Report, vol.2, pp.27-52, 2010.

G. K. Modi and V. Jha, The incidence of end-stage renal disease in India: a population-based study, Kidney Int, vol.70, pp.2131-2133, 2006.

D. H. Smith, C. M. Gullion, G. Nichols, D. S. Keith, and J. B. Brown, Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population, J. Am. Soc. Nephrol, vol.15, pp.1300-1306, 2004.

K. U. Eckardt, J. Coresh, O. Devuyst, R. J. Johnson, A. Köttgen et al., Evolving importance of kidney disease: from subspecialty to global health burden, Lancet, vol.382, pp.158-169, 2013.

R. N. Foley, P. S. Parfrey, and M. J. Sarnak, Epidemiology of cardiovascular disease in chronic renal disease, J. Am. Soc. Nephrol, vol.9, pp.16-23, 1998.

K. Matsushita, M. Van-der-velde, B. C. Astor, M. Woodward, A. S. Levey et al., Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative metaanalysis, Lancet, vol.375, pp.2073-2081, 2010.

A. Levin, J. Singer, C. R. Thompson, H. Ross, and M. Lewis, Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention, Am. J. Kidney Dis, vol.27, pp.347-354, 1996.

P. Raggi, J. Bommer, and G. M. Chertow, Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer, J. Heart. Valve. Dis, vol.13, pp.134-141, 2004.

G. M. London, A. P. Guérin, S. J. Marchais, F. Métivier, B. Pannier et al., Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality, Nephrol. Dial. Transplant, vol.18, pp.1731-1740, 2003.

M. Asami, K. Tanabe, S. Ito, E. Yoshida, J. Aoki et al., Impact of Indoxyl Sulfate on Coronary Plaques in Patients on Hemodialysis, Int. Heart. J, vol.59, pp.489-4968, 2018.

T. Iyanagi, Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification, Int. Rev. Cytol, vol.260, pp.35-112, 2007.

C. Köhle and K. W. Bock, Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor, Biochem. Pharmacol, vol.77, pp.689-699, 2009.

C. Xu, C. Y. Li, and A. N. Kong, Induction of phase I, II and III drug metabolism/transport by xenobiotics, Arch. Pharm. Res, vol.28, pp.249-268, 2005.

M. Kot and W. A. Daniel, Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat, Pharmacol Rep, vol.60, pp.789-797, 2008.

A. Ohnishi, M. Kato, J. Kojima, H. Ushiama, M. Yoneko et al., Differential pharmacokinetics of theophylline in elderly patients, Drugs Aging, vol.20, pp.71-84, 2003.

T. Uno, R. Nakano, R. Kitagawa, M. Okada, K. Kanamaru et al., Metabolism of steroids by cytochrome P450 2C9 variants, Biopharm Drug Dispos, vol.39, pp.371-377, 2018.

K. Seden, L. Dickinson, S. Khoo, and D. Back, Grapefruit-drug interactions, Drugs, vol.70, pp.2373-2407, 2010.

F. J. Gonzalez, R. H. Tukey, and . Chapter, Drug Metabolism. In Goodman & Gilman's. The Pharmacological Basis of Therapeutics, 1996.

J. L. Bolton and M. Chang, Quinoids as reactive intermediates in estrogen carcinogenesis, Adv. Exp. Med. Biol, vol.500, pp.497-507, 2001.

C. Köhle and K. W. Bock, Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2, Biochem. Pharmacol, vol.73, pp.1853-1862, 2007.

F. J. Sharom, ABC multidrug transporters: Structure, function and role in chemoresistance, Pharmacogenomics, vol.9, pp.105-127, 2008.

M. Roth, A. Obaidat, B. Hagenbuch, and . Oatps, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies, Br. J. Pharmacol, vol.165, pp.1260-1287, 2012.

S. K. Nigam, What do drug transporters really do?, Nat. Rev. Drug. Discov, vol.14, pp.29-44, 2015.

S. K. Nigam, W. Wu, K. T. Bush, M. P. Hoenig, R. C. Blantz et al., Handling of Drugs, Metabolites, and Uremic Toxins by Kidney Proximal Tubule Drug Transporters, Clin. J. Am. Soc. Nephrol, vol.10, pp.2039-2049, 2015.

D. R. Owens, Repaglinide-prandial glucose regulator: a new class of oral antidiabetic drugs, Diabet. Med, vol.4, pp.28-36, 1998.

S. Schumacher, I. Abbasi, D. Weise, V. Hatorp, K. Sattler et al., Single-and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment, Eur. J. Clin. Pharmacol, vol.57, pp.147-152, 2001.

F. Coulomb, F. Ducret, J. P. Laneury, F. Fiorentini, I. Poggesi et al., Pharmacokinetics of single-dose reboxetine involunteers with renal insufficiency, J. Clin. Pharmacol, vol.40, pp.482-487, 2000.

R. Yuan and J. Venitz, Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs, Int. J. Clin. Pharmacol. Ther, vol.38, pp.245-253, 2000.

N. A. Limdi, M. A. Limdi, L. Cavallari, A. M. Anderson, M. R. Crowley et al., Warfarin dosing in patients with impaired kidney function, Am. J. Kidney Dis, vol.56, pp.823-831, 2010.

K. H. Lee, H. W. Park, J. G. Cho, N. S. Yoon, S. S. Kim et al., Comparison of non-vitamin K antagonist oral anticoagulants and warfarin on clinical outcomes in atrial fibrillation patients with renal dysfunction, Europace, vol.10, pp.69-75, 2015.

T. D. Nolin, R. F. Frye, P. Le, H. Sadr, J. Naud et al., ESRD impairs nonrenal clearance of fexofenadine but not midazolam, J. Am. Soc. Nephrol, vol.20, pp.2269-2276, 2009.

T. C. Dowling, A. E. Briglia, J. C. Fink, D. S. Hanes, P. D. Light et al., Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease, Clin. Pharmacol. Ther, vol.73, pp.427-434, 2003.

L. A. Frassetto, S. Poon, C. Tsourounis, C. Valera, and L. Z. Benet, Effects of uptake and efflux transporter inhibition on erythromycin breath test results, Clin. Pharmacol. Ther, vol.81, pp.828-832, 2007.

F. A. Leblond, M. Petrucci, P. Dubé, G. Bernier, A. Bonnardeaux et al., Downregulation of intestinal cytochrome p450 in chronic renal failure, J. Am. Soc. Nephrol, vol.13, pp.1579-1585, 2002.

F. A. Leblond, L. Giroux, J. P. Villeneuve, and V. Pichette, Decreased in vivo metabolismof drugs in chronic renal failure, Drug. Metab. Dispos, vol.28, pp.1317-1320, 2000.

F. A. Leblond, C. Guévin, C. Demers, I. Pellerin, M. Gascon-barré et al., Downregulation of hepatic cytochrome P450 in chronic renal failure, J. Am. Soc. Nephrol, vol.12, pp.326-332, 2001.

N. Uchida, N. Kurata, K. Shimada, Y. Nishimura, K. Yasuda et al., Changes of hepatic microsomal oxidative drug metabolizing enzymes inchronic renal failure [CRF] rats by partial nephrectomy, Jpn. J. Pharmacol, vol.68, pp.431-439, 1995.

T. J. Velenosi, A. Y. Fu, S. Luo, H. Wang, and B. L. Urquhart, Down-regulation of hepatic CYP3A and CYP2C mediated metabolism in rats with moderate chronic kidney disease, Drug. Metab. Dispos, vol.40, pp.1508-1514, 2012.

R. K. Sindhu and N. D. Vaziri, Upregulation of cytochrome P450 1A2 in chronic renal failure: does oxidized tryptophan play a role?, Adv. Exp. Med. Biol, vol.527, pp.401-407, 2003.

E. Simard, J. Naud, J. Michaud, F. A. Leblond, A. Bonnardeaux et al., Downregulation of hepatic acetylation of drugs in chronic renal failure, J. Am. Soc. Nephrol, vol.19, pp.1352-1359, 2008.

J. Naud, J. Michaud, C. Boisvert, K. Desbiens, F. A. Leblond et al., Down-regulation of intestinal drug transporters in chronic renal failure in rats, J. Pharmacol. Exp. Ther, vol.320, pp.978-985, 2007.

J. Naud, J. Michaud, F. A. Leblond, S. Lefrancois, A. Bonnardeaux et al., Effects of chronic renal failure on liver drug transporters, Drug. Meta. Dispos, vol.36, pp.124-128, 2008.

D. Laouari, R. Yang, C. Veau, I. Blanke, and G. Friedlander, Two apical multidrug transporters, P-gp and MRP2, are differently altered in chronic renal failure, Am. J. Physiol. Renal. Physiol, vol.280, pp.636-645, 2001.

R. Vanholder, R. De-smet, G. Glorieux, A. Argilés, U. Baurmeister et al., Review on uremic toxins: classification, concentration, and interindividual variability, Kidney. Int, vol.63, pp.1934-1943, 2003.

O. Deltombe, W. Van-biesen, G. Glorieux, Z. Massy, A. Dhondt et al., Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis, Toxins, vol.710, pp.3933-3946, 2015.

E. P. Rhee, A. Souza, L. Farrell, M. R. Pollak, G. D. Lewis et al., Metabolite profiling identifies markers of uremia, J. Am. Soc. Nephrol, vol.6, pp.1041-1051, 2010.

H. Mischak, C. Delles, A. Vlahou, and R. Vanholder, Proteomic biomarkers in kidney disease: issues in development and implementation, Nat. Rev. Nephrol, vol.11, issue.4, pp.221-232, 2015.

R. Vanholder, A. Pletinck, E. Schepers, and G. Glorieux, Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update, Toxins, vol.1, p.33, 2018.

A. Ortiz, A. Covic, D. Fliser, D. Fouque, D. Goldsmith et al., Board of theEURECA-m Working Group of ERA-EDTA. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure, Lancet, vol.383, pp.1831-1843, 2014.

R. Vanholder, U. Baurmeister, P. Brunet, G. Cohen, G. Glorieux et al., European Uremic Toxin Work Group. A bench to bedside view of uremic toxins, J. Am. Soc. Nephrol, vol.19, pp.863-870, 2008.

B. Bammens, P. Evenepoel, H. Keuleers, K. Verbeke, and Y. Vanrenterghem, Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients, Kidney Int, vol.69, pp.1081-1087, 2006.

S. Liabeuf, D. V. Barreto, F. C. Barreto, N. Meert, G. Glorieux et al., European Uraemic Toxin Work Group [EUTox]. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease, Nephrol. Dial. Transplant, vol.25, pp.1183-1191, 2010.

F. C. Barreto, D. V. Barreto, S. Liabeuf, N. Meert, G. Glorieux et al., Serum indoxyl sulfate is associated with vascular disease and mortality in chronickidney disease patients, Clin. J. Am. Soc. Nephrol, vol.4, pp.1551-1558, 2009.

L. Dou, M. Sallée, C. Cerini, S. Poitevin, B. Gondouin et al., The cardiovascular effect of the uremic solute indole-3 acetic acid, J. Am. SocNephrol, vol.26, pp.876-887, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01610425

M. Sallée, L. Dou, C. Cerini, S. Poitevin, P. Brunet et al., The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease, Toxins, vol.6, pp.934-949, 2014.

N. Jourde-chiche, L. Dou, F. Sabatier, R. Calaf, C. Cerini et al., Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients, J. Thromb. Haemost, vol.7, pp.1576-1584, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01610439

C. Gao, S. Ji, W. Dong, Y. Qi, W. Song et al., Indolic uremic solutes enhance procoagulant activity of red blood cells through phosphatidylserine exposure and microparticle release, Toxins, vol.7, pp.4390-4403, 2015.

S. Shivanna, K. Kolandaivelu, M. Shashar, M. Belghasim, L. Al-rabadi et al., The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia, J. Am. Soc. Nephrol, vol.27, pp.189-201, 2016.

V. C. Chitalia, S. Shivanna, J. Martorell, M. Balcells, I. Bosch et al., Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor, Circulation, vol.127, pp.365-376, 2013.

B. Gondouin, C. Cerini, L. Dou, M. Sallée, A. Duval-sabatier et al., Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway, Kidney Int, vol.84, pp.733-744, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01610430

D. Pawlak, K. Pawlak, J. Malyszko, M. Mysliwiec, and W. Buczko, Accumulation of toxic products degradation of kynurenine in hemodialyzed patients, Int. Urol. Nephrol, vol.33, pp.399-404, 2001.

D. Pawlak, A. Tankiewicz, and W. Buczko, Kynurenine and its metabolites in the rat with experimental renal insufficiency, J. Physiol. Pharmacol, vol.52, pp.755-766, 2001.

K. Pawlak, A. Kowalewska, M. Mysliwiec, and D. Pawlak, Kynurenine and its metabolites -kynurenic acid and anthranilic acid-are associated with soluble endothelial adhesion molecules and oxidative status in patients with chronic kidney disease, Am. J. Med.Sci, vol.338, pp.293-300, 2009.

C. A. Opitz, U. M. Litzenburger, F. Sahm, M. Ott, I. Tritschler et al., An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor, Nature, vol.5, pp.197-203, 2011.

M. Reyes and L. Z. Benet, Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics, J. Pharm. Sci, vol.100, pp.3831-3842, 2011.

H. Sun, L. Frassetto, and L. Z. Benet, Effects of renal failure on drug transport and metabolism, Pharmacol. Ther, vol.109, pp.1-11, 2006.

T. Sato, H. Yamaguchi, T. Kogawa, T. Abe, and N. Mano, Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver, J. Pharm. Pharm Sci, vol.17, pp.475-484, 2014.

H. Sun, Y. Huang, L. Frassetto, and L. Z. Benet, Effects of uremic toxins on hepatic uptake and metabolism of erythromycin, Drug. Metab. Dispos, vol.32, pp.1239-1246, 2004.

H. A. Mutsaers, P. Caetano-pinto, A. E. Seegers, A. C. Dankers, P. H. Van-den-broek et al., Proximal tubular efflux transporters involved in renal excretion of p-cresyl sulfate and p-cresyl glucuronide: Implications for chronic kidney disease pathophysiology, Toxicol. In. Vitro, vol.29, pp.1868-1877, 2015.

L. V. Sinclair, D. Neyens, G. Ramsay, P. M. Taylor, and D. A. Cantrell, Single cell analysis of kynurenine and System L amino acid transport in T cells, Nat. Commun, vol.9, issue.1, pp.1981-1992, 2018.

J. Michaud, P. Dubé, J. Naud, F. A. Leblond, K. Desbiens et al., Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450, Br. J. Pharmacol, vol.144, pp.1067-1077, 2005.

C. Guévin, J. Michaud, J. Naud, F. A. Leblond, and V. Pichette, Down-regulation of hepatic cytochrome p450 in chronic renal failure: Role of uremic mediators, Br. J. Pharmacol, vol.137, pp.1039-1046, 2002.

H. Liu, R. Narayanan, M. Hoffmann, and S. Surapaneni, The Uremic Toxin Indoxyl-3-Sulfate Induces CYP1A2 In Primary Human Hepatocytes, Drug. Metab. Lett, vol.10, pp.195-199, 2016.

K. M. Weigand, T. J. Schirris, M. Houweling, J. J. Van-den-heuvel, J. B. Koenderink et al., Uremic solutes modulate hepatic bile acid handling and induce mitochondrial toxicity, Toxicol. In Vitro, vol.56, pp.52-56, 2019.

H. A. Mutsaers, . Van-den, L. P. Heuvel, L. H. Ringens, A. C. Dankers et al., Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations, PLoS. One, vol.6, 2011.

A. C. Dankers, H. A. Mutsaers, H. B. Dijkman, . Van-den, L. P. Heuvel et al., Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistanceprotein (BCRP), Biochim. Biophys. Acta, vol.1832, pp.1715-1722, 2013.

K. Matsuo, S. Yamamoto, T. Wakamatsu, Y. Takahashi, K. Kawamura et al., Increased Proinflammatory Cytokine Production and DecreasedCholesterol Efflux Due to Downregulation of ABCG1 in Macrophages Exposed to Indoxyl Sulfate, Toxins, vol.7, pp.3155-3166, 2015.

Y. Akiyama, K. Kikuchi, D. Saigusa, T. Suzuki, Y. Takeuchi et al., Indoxyl sulfate down-regulates SLCO4C1 transporter through up-regulation of GATA3, PLoS ONE, vol.8, 2013.

A. Enomoto, M. Takeda, K. Tak, F. Takayama, R. Noshiro et al., Interactions of human organic anion as well as cation transporters with indoxyl sulfate, Eur. J. Pharmacol, vol.466, pp.13-20, 2003.

T. Deguchi, H. Kusuhara, A. Takadate, H. Endou, M. Otagiri et al., Characterization of uremic toxin transport by organic anion transporters in the kidney, Kidney Int, vol.65, pp.162-174, 2004.

K. Kikuchi, Y. Itoh, R. Tateoka, A. Ezawa, K. Murakami et al., Metabolomic searchfor uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry, J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci, vol.878, pp.2997-3002, 2010.

H. Fujii, F. Nishijima, S. Goto, M. Sugano, H. Yamato et al., Oral charcoal adsorbent [AST-120] prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress, Nephrol. Dial. Transplant, vol.24, pp.2089-2095, 2009.

S. Yamamoto, J. J. Kazama, K. Omori, K. Matsuo, Y. Takahashi et al., Continuous Reduction of Protein-Bound Uraemic Toxins with Improved Oxidative Stress by Using the Oral Charcoal Adsorbent AST-120 in Haemodialysis Patients, Sci. Rep, vol.5, 1438.

G. Schulman, T. Berl, G. J. Beck, G. Remuzzi, E. Ritz et al., Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD, J. Am. Soc. Nephrol, vol.26, pp.1732-1746, 2015.

Y. Koya, S. Uchida, Y. Machi, Y. Shobu, N. Namiki et al., Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the invitro dissolution and in vivo absorption behavior of the drugs, Eur. J. Clin. Pharmacol, vol.72, pp.1353-1361, 2016.

I. Aoyama, A. Enomoto, and T. Niwa, Effects of oral adsorbent on gene expression profile in uremic rat kidney: cDNA array analysis, Am. J. Kidney. Dis, vol.41, pp.8-14, 2003.

T. D. Nolin, K. Appiah, S. A. Kendrick, P. Le, E. Mcmonagle et al., Hemodialysis acutely improves hepatic CYP3A4 metabolic activity, J. Am. Soc. Nephrol, vol.17, pp.2363-2367, 2006.

J. Michaud, T. D. Nolin, J. Naud, M. Dani, J. P. Lafrance et al., Effect of hemodialysis on hepatic cytochrome P450 functional expression, J. Pharmacol. Sci, vol.108, pp.157-163, 2008.

R. Vanholder, N. Van-landschoot, R. De-smet, A. Schoots, and S. Ringoir, Drug protein binding in chronic renal failure: evaluation of nine drugs, Kidney Int, vol.33, pp.996-1004, 1988.

N. Takamura, T. Maruyama, and M. Otagiri, Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia, Clin. Chem, vol.43, pp.2274-2280, 1997.

H. Watanabe, T. Noguchi, Y. Miyamoto, D. Kadowaki, S. Kotani et al., Interaction between two sulfate-conjugated uremic toxins, p-cresyl sulfate and indoxyl sulfate, during binding with human serum albumin, Drug. Metab. Dispos, vol.40, pp.1423-1428, 2012.

J. Li, Y. Wang, X. Xu, W. Cao, Z. Shen et al., Improved dialysis removal of protein-bound uremic toxins by salvianolic acids, Phytomedicine, vol.57, pp.166-173, 2018.

J. C. Schroeder, B. C. Dinatale, I. A. Murray, C. A. Flaveny, Q. Liu et al., The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor, Biochemistry, vol.49, pp.393-400, 2010.

M. S. Denison and S. R. Nagy, Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals, Annu. Rev. Pharmacol. Toxicol, vol.43, pp.309-334, 2003.

T. D. Hubbard, I. A. Murray, and G. H. Perdew, Indole and Tryptophan Metabolism: Endogenous and Dietary Routes to Ah Receptor Activation, Drug. Metab. Dispos, vol.43, pp.1522-1535, 2015.

L. Dou, S. Poitevin, M. Sallée, T. Addi, B. Gondouin et al., Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease, Kidney Int, vol.93, pp.986-999, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02060310

V. B. Kolachalama, M. Shashar, F. Alousi, S. Shivanna, K. Rijal et al., Uremic Solute-Aryl Hydrocarbon Receptor-Tissue Factor Axis Associates with Thrombosis after Vascular Injury in Humans, J. Am. Soc. Nephrol, vol.29, pp.1063-1072, 2018.

M. S. Denison, A. A. Soshilov, G. He, D. E. Degroot, and B. Zhao, Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon [dioxin] receptor, Toxicol. Sci, vol.124, pp.1-22, 2011.

J. Abel and T. Haarmann-stemmann, An introduction to the molecular basics of aryl hydrocarbon receptor biology, Biol. Chem, vol.391, pp.1235-1248, 2010.

T. Ikuta, H. Eguchi, T. Tachibana, Y. Yoneda, and K. Kawajiri, Nuclear localization and export signals of the human aryl hydrocarbon receptor, J. Biol. Chem, vol.273, pp.2895-2904, 1998.

O. Hankinson, Role of coactivators in transcriptional activation by the aryl hydrocarbon receptor, Arch. Biochem. Biophys, vol.433, pp.379-386, 2005.

J. Mimura and Y. Fujii-kuriyama, Functional role of AhR in the expression of toxic effects by TCDD, Biochim. Biophys. Acta, vol.1619, pp.263-268, 2003.

L. C. Quattrochi, T. Vu, and R. Tukey, The human CYP1A2 gene and induction by 3-methylcholanthrene.A region of DNA that supports Ah-receptor binding and promoter-specific induction, J. Biol. Chem, vol.269, pp.6949-6954, 1994.

T. J. Erichsen, U. Ehmer, S. Kalthoff, T. O. Lankisch, T. M. Müller et al., Genetic variability of aryl hydrocarbon receptor [AhR]-mediated regulation of the human UDP glucuronosyltransferase [UGT] 1A4 gene, Toxicol. Appl. Pharmacol, vol.230, pp.252-260, 2008.

Y. Emi, S. Ikushiro, and T. Iyanagi, Xenobiotic responsive element-mediated transcriptional activation in the UDP-glucuronosyltransferase family 1 gene complex, J. Biol. Chem, vol.271, pp.3952-3958, 1996.

W. Li, P. A. Harper, B. K. Tang, and A. B. Okey, Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene, Biochem. Pharmacol, vol.56, pp.599-612, 1998.

T. O. Lankisch, T. C. Gillman, T. J. Erichsen, U. Ehmer, S. Kalthoff et al., Aryl hydrocarbon receptor-mediated regulation of the human estrogen and bile acid UDP-glucuronosyltransferase 1A3 gene, Arch. Toxicol, vol.82, pp.573-582, 2008.

S. Kalthoff, U. Ehmer, N. Freiberg, M. P. Manns, and C. P. Strassburg, Interaction between oxidative stress sensor Nrf2 and xenobiotic-activated aryl hydrocarbon receptor in the regulation of the human phase II detoxifying UDP-glucuronosyl-transferase 1A10, J. Biol. Chem, vol.285, pp.5993-6002, 2010.

J. Zhou, J. Zhang, and W. Xie, Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyl-transferases, Curr. Drug. Metab, vol.6, pp.289-298, 2005.

B. L. Urquhart, R. G. Tirona, and R. B. Kim, Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs, J. Clin. Pharmacol, vol.47, pp.566-578, 2007.

V. Vasiliou, T. Buetler, D. L. Eaton, and D. W. Nebert, Comparison of oxidative stress response parameters in newborn mouse liver versus simian virus 40 [SV40]-transformed hepatocyte cell lines, Biochem. Pharmacol, vol.59, pp.703-712, 2000.

X. Gao, C. Xie, Y. Wang, Y. Luo, T. Yagai et al., The antiandrogen flutamide is a novel aryl hydrocarbon receptor ligand that disrupts bile acid homeostasis in mice through induction of Abcc4, Biochem. Pharmacol, vol.119, pp.93-104, 2016.

L. Vee, M. Jouan, E. Stieger, B. Lecureur, V. Fardel et al., Regulation of human hepatic drug transporter activity and expression by diesel exhaust particle extract, PLoS One, vol.10, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01138535

L. Vee, M. Jouan, E. Lecureur, V. Fardel, and O. , Aryl hydrocarbon receptor-dependent up-regulation of the heterodimeric amino acid transporter LAT1 [SLC7A5]/CD98hc [SLC3A2] by diesel exhaust particle extract in human bronchial epithelial cells, Toxicol. Appl. Pharmacol, vol.290, pp.74-85, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01237095

S. Machado, T. Poitevin, S. Paul, P. Mckay, N. Jourde-chiche et al., Indoxyl Sulfate Upregulates Liver P-Glycoprotein Expression and Activity through Aryl Hydrocarbon Receptor Signaling, J. Am. Soc. Nephrol, vol.29, pp.906-918, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02060562

S. F. Zhou, E. Chan, Z. W. Zhou, C. C. Xue, X. Lai et al., Insights into the structure, function, and regulation of human cytochrome P450 1A2, Curr. Drug. Metab, vol.10, pp.713-729, 2009.

S. F. Zhou, B. Wang, L. P. Yang, and J. P. Liu, Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2, Drug. Metab. Rev, vol.42, pp.268-354, 2010.

A. Za'abi, M. Shalaby, A. Manoj, P. Ali, and B. H. , The in vivo effects of adenine-induced chronic kidney disease on some renal and hepatic function and CYP450 metabolizing enzymes, Physiol. Res, vol.66, pp.263-271, 2017.

G. Smith, C. R. Wolf, Y. Y. Deeni, R. S. Dawe, A. T. Evans et al., Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases, Lancet, vol.361, pp.1336-1343, 2003.

S. P. Rivera, F. Wang, S. T. Saarikoski, R. T. Taylor, B. Chapman et al., A novel promoter element containing multiple overlapping xenobiotic and hypoxia response elements mediates induction of cytochrome P4502S1 by both dioxin and hypoxia, J. Biol. Chem, vol.282, pp.10881-10893, 2007.

D. W. Nebert and D. W. Russell, Clinical importance of the cytochromes P450, Lancet, vol.360, pp.1155-1162, 2002.

E. T. Oh and H. J. Park, Implications of NQO1 in cancer therapy, BMB. Rep, vol.48, pp.609-617, 2015.

N. E. Ládek, R. Kollander, L. Sreerama, and D. T. Kiang, Cellular levels of aldehyde dehydrogenases [ALDH1A1 and ALDH3A1] as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens, Cancer. Chemother. Pharmacol, vol.49, pp.309-321, 2002.

B. Parajuli, T. M. Georgiadis, M. L. Fishel, and T. D. Hurley, Development of selective inhibitors for human aldehyde dehydrogenase 3A1 [ALDH3A1] for the enhancement of cyclophosphamide cytotoxicity, Chembio. Chem, vol.15, pp.701-712, 2014.

C. Ghosh, M. Hossain, V. Puvenna, J. Martinez-gonzalez, A. Alexopolous et al., Expression and functional relevance of UGT1A4 in a cohort of human drug-resistant epileptic brains, Epilepsia, vol.54, pp.1562-1570, 2013.

Z. Mazerska, A. Mróz, M. Paw?owska, and E. Augustin, The role of glucuronidation in drug resistance, Pharmacol. Ther, vol.159, pp.35-55, 2016.

K. K. Erickson-ridout, D. Sun, and P. Lazarus, Glucuronidation of the secondgeneration antipsychotic clozapine and its active metabolite N desmethylclozapine, Pharmacogenet. Genomics, vol.22, pp.561-576, 2012.

O. Kerdpin, K. M. Knights, D. J. Elliot, and J. O. Miners, In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway, Biochem. Pharmacol, vol.76, pp.249-257, 2008.

A. Yamada, K. Maeda, N. Ishiguro, Y. Tsuda, T. Igarashi et al., The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokineticsof telmisartan in healthy volunteers, Pharmacogenet. Genomics, vol.21, pp.523-530, 2011.

E. S. Jeong, Y. W. Kim, H. J. Kim, H. J. Shin, J. G. Shin et al., Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3, Xenobiotica, vol.45, pp.10-18, 2015.

S. K. Cho, E. S. Oh, K. Park, M. S. Park, and J. Y. Chung, The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid lowering effect in healthy volunteers, Pharmacogenet. Genomics, vol.22, pp.598-605, 2012.

H. Fujino, I. Yamada, S. Shimada, M. Yoneda, and J. Kojima, Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: Human UDP-glucuronosyltransferase enzymes involved in lactonization, Xenobiotica, vol.33, pp.27-41, 2003.

T. Prueksaritanont, R. Subramanian, X. Fang, B. Ma, Y. Qiu et al., Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization, Drug. Metab. Dispos, vol.30, pp.505-512, 2002.

T. J. Schirris, T. Ritschel, A. Bilos, J. A. Smeitink, and F. G. Russel, Statin Lactonization by Uridine 5'-Diphospho-glucuronosyltransferases

, Mol. Pharm, vol.2, pp.4048-4055, 2015.

C. Vanlersberghe, F. Camu, and . Propofol, Handb. Exp. Pharmacol, vol.182, pp.227-252, 2008.

A. Sharma, B. Patrick, J. Li, R. Sharma, P. V. Jeyabal et al., Glutathione S-transferases as antioxidant enzymes: Small cell lung cancer [H69] cells transfected with hGSTA1 resist doxorubicin-induced apoptosis, Arch. Biochem. Biophys, vol.45, pp.165-173, 2006.

K. P. Locher, Structure and mechanism of ATP-binding cassette transporters, Philos.Trans. R. Soc. Lond. B. Biol. Sci, vol.364, pp.239-245, 2009.

G. Chang, Multidrug resistance ABC transporters, FEBS. Lett, vol.555, pp.102-105, 2003.

C. H. Choi, ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal, Cancer. Cell. Inter, vol.5, pp.1-13, 2005.

S. M. He, R. Li, J. R. Kanwar, and S. F. Zhou, Structural and functional properties of human multidrug resistance protein 1

, Curr. Med. Chem, vol.18, pp.439-481, 2011.

M. Gynther, K. Laine, J. Ropponen, J. Leppänen, A. Mannila et al., Large neutral amino acid transporter enables brain drug delivery via prodrugs, J. Med. Chem, vol.51, pp.932-936, 2008.

E. M. Del-amo, A. Urtti, and M. Yliperttula, Pharmacokinetic role of L-type amino acidtransporters LAT1 and LAT2, Eur. J. Pharm. Sci, vol.35, pp.161-174, 2008.

P. Gomes and P. Soares-da-silva, Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells, Neuropharmacology, vol.38, pp.1371-1380, 1999.

T. Kageyama, M. Nakamura, A. Matsuo, Y. Yamasaki, Y. Takakura et al., The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier, Brain. Res, vol.879, pp.115-121, 2000.

Y. Kido, I. Tamai, H. Uchino, F. Suzuki, Y. Sai et al., Molecular and functional identification of large neutral amino acid transporters LAT1 and LAT2 and their pharmacological relevance at the blood-brain barrier, J. Pharm. Pharmacol, vol.53, pp.497-503, 2001.

B. Sampaio-maia, M. P. Serrão, and P. Soares-da-silva, Regulatory pathways and uptake of L-DOPA by capillary cerebral endothelial cells, astrocytes, and neuronal cells, Am. J. Physiol. Cell. Physiol, vol.280, pp.333-342, 2001.

P. Soares-da-silva, P. Serrão, S. Fraga, and M. J. Pinho, Expression and function of LAT1, a neutral amino acid exchanger, in renal porcine epithelial cell line LLC-PK, Acta. Physiol. Scand, vol.185, pp.71-78, 2005.

S. Fraga, B. Sampaio-maia, M. P. Serrão, and P. Soares-da-silva, Regulation of apical transporter of L-DOPA in human intestinal Caco-2 cells, Acta. Physiol. Scand, vol.175, pp.103-111, 2002.